Silence Therapeutics PLC(SLN) - 2025 Q4 - Annual Report

Financial Performance - The company reported net losses of $88.6 million for the year ended December 31, 2025, and $45.3 million for the year ended December 31, 2024, with an accumulated deficit of $562.6 million as of December 31, 2025[190]. - The company expects to continue incurring significant operating losses, with expenses anticipated to increase substantially due to ongoing research and development activities[191]. - As of December 31, 2025, the company had cash and cash equivalents of $85.1 million, which is expected to cover liabilities for at least the next twelve months[200]. - The company may need to seek additional funding sooner than planned if costs exceed expectations or if operational plans change[200]. - The company acknowledges that the inability to obtain future funding could impact its financial condition and ability to pursue business strategies[202]. Revenue Generation - The company has never generated any revenue from product sales and does not anticipate doing so for the foreseeable future[192]. - The company cannot predict the timing of revenue from future product candidates due to uncertainties in obtaining regulatory approvals[236]. - The company may not achieve market acceptance necessary for commercial success, impacting revenue generation[256]. Research and Development - The company has concentrated its research and development efforts on siRNA technology, which is relatively new and may not lead to marketable products[208]. - The company has two proprietary product candidates currently in clinical development, with other candidates in preclinical stages[220]. - Clinical trials are expensive and can take many years to complete, with a high risk of failure at any stage[220]. - The success of the company's product candidates depends on the successful completion of clinical trials, which may face significant delays or failures[214]. - Delays in clinical trial commencement or completion could lead to increased costs and impair the ability to generate revenues from product sales[222]. Regulatory Compliance - Regulatory approval for product candidates is contingent on successful clinical trials demonstrating safety and efficacy[220]. - The company must maintain compliance with various regulatory authorities to avoid delays or denials in marketing approvals[221]. - The company faces increased compliance costs and regulatory investigations related to the use of AI technologies in its operations[283]. - The company is subject to stringent and evolving data privacy and security laws, and any perceived failure to comply could lead to regulatory investigations, litigation, and reputational harm[277]. Competition - The company faces competition from various sources, including major pharmaceutical companies and biotechnology firms, which may have more resources and experience[257]. - The company may face increased competition even with orphan drug exclusivity, as other therapies can be approved for the same condition[250]. - The company faces significant competition from other firms that may develop safer, more effective, or less expensive products, potentially reducing its market opportunity[258]. Intellectual Property - The company relies on a combination of patents, trade secret protection, and confidentiality agreements to protect its intellectual property, but there is uncertainty regarding the strength and enforceability of these protections[306]. - The company may encounter significant challenges in protecting its intellectual property rights in jurisdictions outside the United States, which could adversely affect its competitive advantage[311]. - Third-party claims of intellectual property infringement could delay the company's development and commercialization efforts, impacting its commercial success[312]. Management and Operations - The company is highly dependent on retaining key executives and attracting qualified personnel, with a current employee count of 86 as of December 31, 2025, and plans for future expansion[261][263]. - Future growth may impose additional responsibilities on management, potentially leading to operational mistakes and increased expenses if not managed effectively[263]. - The company may incur substantial litigation expenses and management distraction due to potential patent infringement claims, which could impact its ability to commercialize product candidates[314]. Taxation and Financial Regulations - The company may identify material weaknesses in its internal control over financial reporting in the future, which could adversely affect its business[333]. - The company's consolidated effective income tax rate may be adversely affected by changing tax laws and regulations in the U.K., Germany, and the U.S.[358]. - Tax authorities may challenge the company's tax positions, potentially leading to increased tax liabilities and impacting financial condition[359]. Shareholder Matters - Approximately 46% of the company's issued and outstanding ordinary shares are beneficially owned by senior management, directors, and principal shareholders, potentially limiting new investors' influence on corporate decisions[331]. - The company has never declared or paid a dividend on its ordinary shares and intends to retain future earnings to fund development, making capital appreciation the sole source of gains for investors[332]. - Holders of ADSs may face limitations on their rights and may not receive timely voting materials, affecting their ability to participate in shareholder meetings[338]. Legal and Jurisdictional Issues - The company may face challenges in enforcing U.S. civil liabilities due to its incorporation under English law and the location of its assets outside the U.S.[371]. - There is currently no treaty between the U.S. and the U.K. for the reciprocal recognition and enforcement of judgments, which may complicate legal proceedings[372]. - U.S. investors may face challenges in enforcing judgments against the company or its management in U.S. courts due to jurisdictional issues[373].